GenSight Biologics Announces Publication of Results of LUMEVOQ® REFLECT Pivotal Clinical Trial in Peer-Reviewed Journals

GenSight Biologics secures a €35 million credit facility from the European Investment Bank to support the launch of LUMEVOQ® in Europe

GenSight Biologics Reports Cash Position and Revenues as of September 30, 2022

GenSight Biologics to Present at Upcoming 2022 Medical Conferences

GenSight Biologics to Present at Upcoming Industry and Investor Conferences

GenSight Biologics Announces Successful Completion of LUMEVOQ® Engineering Batch Validating Implemented Corrective Actions

GenSight Biologics strengthens its management team to support the launch of LUMEVOQ® in Europe

GenSight Biologics Reports Interim Financial Results for the First Half of 2022

GenSight Biologics reports 5 years’ data showing sustained efficacy and safety following one-time treatment with LUMEVOQ®

GenSight Biologics Announces Participation and Presentation of GS010 Clinical Data at EUNOS 2022